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Introduction
FGFs are among the most potent inducers of endothelial cell 
migration, which is a critical event in angiogenesis and numer-
ous other biological processes. FGFs signal via four high-affinity 
tyrosine kinase receptors (FGFR1–4) and the low-affinity hep-
aran sulfate proteoglycan, syndecan 4 (S4; Murakami et al., 
2008). The ability of S4 to signal independently of FGF recep-
tors is largely credited to its ability to activate PKC (Horowitz 
et al., 1999; Partovian et al., 2008) and to assemble a signaling 
complex via its postsynaptic density disc large ZO-1 (PDZ)–
binding domain. This domain mediates S4’s association with 
synectin, a ubiquitous PDZ-containing 38-kD cytoplasmic pro-
tein (Gao et al., 2000).
Studies involving the deletions of S4 and synectin have 
demonstrated their respective roles in physiological events as 
diverse as wound healing (Alexopoulou et al., 2007), arterial 
development (Chittenden et al., 2006; Dedkov et al., 2007), 
endotoxic shock protection (Ishiguro et al., 2001), murine vibris-
sae growth (Iwabuchi and Goetinck, 2006), and neural crest de-
velopment  (Matthews  et  al.,  2008). Although  the  molecular 
causes of these phenotypes remain largely undefined, S4–
synectin signaling is known to target the small Rho family GTPase 
Rac1 (Tkachenko et al., 2006; Matthews et al., 2008), which or-
chestrates actin polymerization in migrating cells.
Rac1 can be activated via several parallel pathways, and 
its active form is typically found in highest concentrations at the 
plasma membrane of migrating cells’ leading edges. One up-
stream activator of Rac1 is the highly homologous small Rho 
GTPase, RhoG. This protein has been specifically implicated 
in cell migration, activating Rac1 upon binding ELMO and 
  F
ibroblast growth factor 2 (FGF2) is a major regulator 
of  developmental,  pathological,  and  therapeutic 
angiogenesis. Its activity is partially mediated by 
binding to syndecan 4 (S4), a proteoglycan receptor.   
Angiogenesis requires polarized activation of the small 
guanosine triphosphatase Rac1, which involves localized 
dissociation  from  RhoGDI1  and  association  with  the 
plasma membrane. Previous work has shown that genetic 
deletion of S4 or its adapter, synectin, leads to depolar-
ized Rac activation, decreased endothelial migration, and 
other physiological defects. In this study, we show that 
Rac1  activation  downstream  of  S4  is  mediated  by  the 
RhoG  activation  pathway.  RhoG  is  maintained  in  an   
inactive state by RhoGDI1, which is found in a ternary 
complex with synectin and S4. Binding of S4 to synectin 
increases the latter’s binding to RhoGDI1, which in turn 
enhances RhoGDI1’s affinity for RhoG. S4 clustering acti-
vates PKC, which phosphorylates RhoGDI1 at Ser
96. This 
phosphorylation  triggers  release  of  RhoG,  leading  to 
polarized activation of Rac1. Thus, FGF2-induced Rac1 
activation depends on the suppression of RhoG by a pre-
viously uncharacterized ternary S4–synectin–RhoGDI1 pro-
tein complex and activation via PKC.
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signal via its high-affinity tyrosine kinase receptor or via S4, we 
examined whether S4 clustering alone is sufficient to activate 
RhoG. The  activity  of  RhoG  was  measured  upon  antibody-
  induced clustering of an S4 chimera, which contains human Fc 
receptor (FcR) 1a (CD64) in place of the extracellular domain 
(Tkachenko and Simons, 2002). S4-FcR clustering led to RhoG 
activation (Fig. 1 b) with kinetics comparable with those of 
Rac1 activation by S4-FcR clustering (Tkachenko et al., 2006).
We next tested the requirement for RhoG in FGF2-induced 
Rac activation using two approaches for RhoG inhibition. First, 
RFPECs  were  transfected  with  wild-type  (WT)  RhoG, A37 
RhoG (which does not bind its effector, ELMO), or V12 RhoG 
(constitutively active). Measurement of Rac activity in cell 
lysates 10 min after FGF2 stimulation demonstrated a 1.5-fold 
increase in cells expressing WT RhoG (Fig. 1 c), whereas A37 
RhoG  significantly  blunted  Rac1  activation.  Conversely,  the 
constitutively active V12 RhoG mutant induced high Rac1 
activity that did not change after FGF2 treatment. Second, we 
examined the effect of knocking down RhoG expression, in this 
case measuring Rac1 activity in live cells using an intramolecu-
lar fluorescence resonance energy transfer (FRET) probe (Raichu-
Rac1). This probe measures the local balance of GEF and GAP 
activities but is insensitive to regulation by RhoGDI (Itoh et al., 
2002). In control cells, FGF2 increased Rac1 activity between 
5 and 10 min (Fig. 1 d, top), whereas in cells expressing RhoG 
short hairpin RNA (shRNA), Rac1 baseline activity was reduced 
(Fig. S1 b), and stimulation by FGF2 was inhibited (Fig. 1,   
d [bottom] and e). These results confirm the effects of the RhoG 
dominant negative and indicate that changes in GEF or GAP 
activity, rather than RhoGDI, must mediate the effect.
We next investigated whether RhoG is required for FGF2-
induced cell migration. Knockdown of RhoG diminished endo-
thelial cell migration in response to FGF2, whereas expression 
of V12 RhoG potentiated cell migration (Fig. 1 f). Collectively, 
these data demonstrate that FGF2 activates RhoG via S4, that 
RhoG is required for Rac1 activation, and that RhoG mediates 
FGF2-induced cell migration.
S4  is  required  to  maintain  low  baseline  Rac1  activity   
(Saoncella et al., 2004; Tkachenko et al., 2006; Bass et al., 2007), 
although the mechanism of this effect is unknown. Given our find-
ing that both baseline Rac1 activity and its stimulation by FGF2 
depend on RhoG, we investigated whether S4 likewise affects 
Rac1 baseline activity via RhoG. To begin, measurement of base-
line RhoG activity in pulmonary microvascular endothelial cells 
from S4
+/+ and S4
/ mice showed that loss of S4 significantly in-
creased baseline RhoG activity (Fig. 2 a). The S4 cytoplasmic tail 
contains a PDZ-binding sequence that interacts with synectin, a 
ubiquitously expressed protein that also affects Rac1 activity (Gao 
et al., 2000; Chittenden et al., 2006). A yeast two-hybrid screen 
with synectin as bait revealed S4 and RhoGDI1 as binding part-
ners (unpublished data). RhoGDI1 regulates the activity of Rho 
family GTPases by preventing interactions with GEFs. Therefore, 
we explored whether S4 influences RhoG activity through synec-
tin and RhoGDI1. A biotinylated, synthetic peptide corresponding 
to the transmembrane and cytoplasmic domains of S4 bound not 
only synectin as expected (Fig. 2 b, top) but also pulled down 
RhoGDI (Fig. 2 b, bottom) from RFPEC lysates.
Dock180 (Katoh and Negishi, 2003; Katoh et al., 2006). RhoG 
is ubiquitously expressed and is a principal mediator of two sep-
arate endocytic pathways: macropinocytosis and caveolar endo-
cytosis (Ellerbroek et al., 2004; Prieto-Sanchez et al., 2006). 
RhoG-mediated endocytosis is also exploited during infection 
by Salmonella (Patel and Galan, 2006) and Shigella (Handa et al., 
2007) and is required for endothelial apical cup formation dur-
ing leukocyte extravasation (van Buul et al., 2007).
The activation of Rho GTPases is primarily regulated 
by the guanine exchange factor (GEF) class of proteins. GEFs   
catalyze the exchange of GDP for GTP on their targets, whereas 
GTPase-activating  proteins  (GAPs)  accelerate  the  intrinsic   
GTPase activity of these proteins and facilitate their rapid in-
activation. In this way, the trimeric complex of RhoG, ELMO, and 
Dock180 functions as a GEF in the activation of Rac1 (Katoh 
and Negishi, 2003). A third class of proteins, guanine dissocia-
tion inhibitors (GDIs), serves to sequester pools of inactive   
GTPases, shielding them from GEF and GAP interactions. 
Three Rho family GTPase-interacting GDIs have been identi-
fied (RhoGDI1–3) with some degree of overlap in their GTPase 
targets (Dovas and Couchman, 2005).
We and others have shown that the genetic knockout of   
either S4 or synectin results in a signaling defect whereby cells 
exhibit a constitutively high level of Rac1 activity (Saoncella 
et al., 2004; Chittenden et al., 2006; Tkachenko et al., 2006; Bass 
et al., 2007; Matthews et al., 2008). These cells migrate poorly 
as a result of the mislocalization and overabundance of active 
Rac1, and mice with the constitutive signaling imbalance dis-
play various physiological abnormalities (Pankov et al., 2005; 
Chittenden et al., 2006; Partovian et al., 2008). Correct spatial 
and temporal regulation of Rac1 activity is therefore an indis-
pensable prerequisite for directional cell migration, angiogenesis, 
and normal cardiovascular function.
In this study, we sought to identify (a) the mechanism of 
basal GTPase suppression before stimulation and (b) how Rac1 
becomes activated downstream of S4 during endothelial cell 
migration. We report that S4-mediated Rac1 activation proceeds 
via  the  RhoG–Dock180–ELMO  pathway.  Before  activation, 
RhoGDI1 keeps RhoG inactive and sequestered as part of a pre-
viously uncharacterized protein complex with S4 and synectin. 
Upon FGF2 treatment, S4 oligomerization leads to PKC acti-
vation, resulting in the phosphorylation of RhoGDI1 at Ser
96. 
Phosphorylation  initiates  the  release  of  RhoG  from  the  S4–
  synectin–RhoGDI protein complex and permits its activation, 
which in turn induces the polarized activation of Rac1.
Results
Rac1, a critical component of endothelial cell migration, can   
be activated by RhoG through the DOCK180–ELMO complex 
(Katoh and Negishi, 2003). Because RhoG plays a prominent 
role in endothelial cells (van Buul et al., 2007), we examined 
the involvement of RhoG in Rac1 activation when endothelial 
cells respond to FGF2. RhoG activity increased when rat fat pad 
endothelial cells (RFPECs) were stimulated with FGF2, peak-
ing at 10 min (Fig. 1 a). These kinetics also mirrored those of 
FGF2-induced Rac1 activation (Fig. S1 a). Because FGF2 can 77 SYNDECAN 4 REGULATES RhoG ACTIVITY • Elfenbein et al.
required to bind synectin, these data demonstrate the importance 
of S4–synectin interaction in synectin’s binding to RhoGDI1.
Whether RhoG associates with this S4–synectin–RhoGDI1 
complex was studied next. Published data are inconsistent on 
whether RhoG binds RhoGDI1 (Fauré and Dagher, 2001; Brunet 
et al., 2002). We found that glutathione beads conjugated 
with recombinant GST-RhoGDI1 bound both synectin and 
RhoG from RFPEC lysates, whereas control beads showed 
Next, we performed coimmunoprecipitations using anti-
bodies against each protein. RhoGDI immunoprecipitates con-
tained synectin in WT RFPECs and in RFPECs overexpressing 
the S4-FcR chimera but not in RFPEC overexpressing the S4 chi-
mera containing a nonfunctional PDZ-binding domain (Fig. 2 c, 
top). Synectin immunoprecipitation also brought down less 
RhoGDI in these cells compared with S4-overexpressing or WT 
S4 (Fig. 2 c, middle). Because the PDZ-binding domain of S4 is 
Figure 1.  FGF2 and S4 clustering activate Rac1 via RhoG. (a) RFPECs were cultured in 0.5% FBS/DME for 24 h before RhoG activity assay. Cells were 
treated with 50 ng/ml FGF2 for the indicated times before lysis and subsequent RhoG activity assay. Peak RhoG activity is observed at 10 min. (right) Quan-
tification from three experiments is shown. *, P = 0.018. (b) RFPECs stably expressing the S4-FcR chimera were likewise cultured for 24 h in 0.5% FBS/DME 
before RhoG activity assay. The S4-FcR chimera was clustered for the indicated times. (right) Quantification from three experiments is shown. *, P = 0.042. 
(c) RFPECs were transfected with the indicated RhoG constructs for 48 h before assay. 24 h after transfection, cells were cultured in 0.5% FBS/DME. Each 
condition represents no stimulation () or 10 min of FGF2 stimulation at a concentration of 50 ng/ml (+). Rac1 activity assays were performed three times and 
quantified using a modified ELISA technique (see Materials and methods). * (left to right), P = 0.0008, 0.014, and 0.002. (d) RFPECs were plated on glass 
coverslips and transfected with Raichu-Rac1 along with the indicated shRNA constructs in a 1:4 molar ratio. Cells were serum starved with 0.5% FBS in 1:1 
F12/DME for 12 h before imaging. FGF2 was added at the indicated time points, and the cells were imaged once per minute. The images show the pseudo-
colored FRET ratios calculated as YFP fluorescence/CFP fluorescence after background subtraction at each pixel. Higher ratio values (red) correlate with higher 
Rac1 activity. Bars, 10 µm. (e) Quantification of whole cell FRET ratios across six cells were performed in each condition shown in d. FGF2 stimulation (+) is 
for 10 min. *, P = 0.037. (f) RFPECs were transfected with the indicated constructs and plated on fibronectin-coated plastic dishes. The cells were grown to a 
confluent monolayer, at which time they were serum starved, and a scratch was introduced to disrupt the monolayer. The images and quantification represent 
the area migrated, averaged over three experiments with 24 frames measured per condition, 24 h after monolayer disruption. All results were normalized to 
the migration of nonstimulated control cells (leftmost condition). Constitutively active RhoG (V12) was used as a positive control for migration. * (bottom to top), 
P = 0.048 and 0.008. Bars, 75 µm. P-values in all experiments were calculated using a two-sample equal variance t test. Error bars represent SEM.JCB • VOLUME 186 • NUMBER 1 • 2009   78
approaches. First, the effect of overexpressed synectin on bind-
ing of RhoG to recombinant GST-tagged RhoGDI1 was exam-
ined. RFPECs were transfected with His-tagged synectin or 
GFP as a control. Expression of synectin substantially increased 
binding of endogenous RhoG to RhoGDI1 beads (Fig. 3 b, 
compare left with middle), whereas no binding was observed to 
glutathione beads alone (Fig. 3 b, right). Interestingly, synectin 
overexpression also enhanced RhoGDI–Rac1 binding (Fig. S1 h). 
Second, we examined the effect of synectin knockout on the 
ability of RhoGDI1 to bind RhoG. In murine lung endothelial 
cells,  immunoprecipitation  of  RhoGDI1  brought  down  less 
RhoG in synectin
/ cells than in WT cells (Fig. 3 c). Collectively, 
these data demonstrate that synectin enhances both the binding 
of RhoG by RhoGDI and the suppression of RhoG activity.
To test whether RhoGDI is required for suppression of 
RhoG by S4 and synectin, we measured the effect of RhoGDI1 
knockdown on RhoG activity in RFPECs (Fig. 3 d). In control 
shRNA-treated cells, FGF2 treatment elevated RhoG activity   
by 1.5-fold after 10 min (Fig. 3 d, left). In cells treated with 
shRNA against RhoGDI1, baseline RhoG activity was approx-
imately twofold higher than in control cells, and FGF2 triggered 
no further increase (Fig. 3 d, right). Related experiments involv-
ing RhoGDI2 (Ly-GDI or GDI-D4) have shown the ability of 
this GDI to affect the activity states of other Rho family GTPases 
no binding (Fig. 2 d). The use of purified RhoGDI1 in combina-
tion with a specific anti-RhoG antibody (Meller et al., 2008) in 
these experiments provides strong evidence for this interaction. 
The cellular distribution of RhoG in living cells also changes in 
a RhoGDI1-dependent manner, further demonstrating the inter-
action of these two proteins (Fig. S1 c). We finally sought to con-
firm the existence of this protein complex within intact cells. The 
S4-FcR chimera was expressed and stained in RFPECs (Fig. 2 e). 
Despite the largely cytoplasmic distribution of RhoGDI1, cer-
tain membrane regions demonstrated colocalization of the S4 
construct (Fig. 2 e, left), RhoGDI1 (Fig. 2 e, middle), and RhoG 
(Fig. 2 e, right). Validation of the RhoG monoclonal antibody for 
immunofluorescence is presented in Fig. S1 (d–f).
We hypothesized that the interaction between RhoG and 
RhoGDI1 is regulated, which may account for the contradictory 
reports in different studies (Fauré and Dagher, 2001; Brunet   
et al., 2002). To test whether synectin enhances RhoGDI’s affin-
ity for RhoG, we measured the effect of synectin overexpres-
sion in RFPECs on RhoG activity (Fig. 3 a). Consistent with our 
hypothesis, synectin overexpression decreased RhoG activity 
(Fig. 3 a), and endothelial cells from synectin knockout mice were 
also found to have high basal levels of RhoG activity (Fig. S1 g). 
To test whether synectin suppresses RhoG activity by increas-
ing RhoGDI’s affinity for RhoG, we used two complementary 
Figure 2.  S4 mediates baseline RhoG activity and associates with synectin, RhoGDI1, and RhoG. (a) Murine pulmonary microvascular endothelial cells 
from WT and S4 knockout mice were cultured in 0.5% FBS/DME for 24 h before assay of RhoG activity. -Actin and RhoGDI were used as loading controls. 
(right) Quantification from three experiments is shown. *, P = 0.009. Error bar indicates SEM. (b) A synthetic biotinylated peptide corresponding to the 
transmembrane domain and cytoplasmic tail of S4 was used to pull down proteins after conjugation to streptavidin beads. Pull-downs were immunoblotted 
and probed for synectin (top) and RhoGDI (bottom).  indicates unconjugated streptavidin beads. In both cases, the target proteins were pulled down only 
when incubated with the S4 tail peptide. (c) Coimmunoprecipitations were performed with antibodies against RhoGDI and synectin in three cell lines: WT 
RFPECs (left), RFPECs expressing the S4-FcR chimera (middle), and RFPECs expressing the S4-FcR (PDZ) chimera (right). -Actin was used as a loading 
control. IP, immunoprecipitation. (d) Glutathione beads conjugated with recombinant RhoGDI1 (right) or without the recombinant protein (left) were incu-
bated with lysates of RFPECs for 12 h at 4°C. After washing, proteins were denatured by boiling and subjected to SDS-PAGE. The proteins were transferred 
to a membrane and probed for RhoG and synectin. (e) RFPECs were transfected with the S4-FcR chimera. Cells were incubated with FITC-conjugated human 
IgG to stain the chimera (left), washed twice with PBS, fixed, permeabilized, and stained with antibodies against RhoGDI1 and RhoG (middle and right, 
respectively). Arrows indicate regions of colocalization. Bars, 10 µm.79 SYNDECAN 4 REGULATES RhoG ACTIVITY • Elfenbein et al.
in Fig. S1, j and k). RhoGDI1 Ser
96 phosphorylation was detected 
within 1 min after clustering the S4-FcR chimera and then   
returned to a lower plateau level (Fig. 4 c). Thus, RhoGDI1 
phosphorylation precedes RhoG and Rac1 activation. To estab-
lish a functional role for RhoGDI1 Ser
96 phosphorylation, we 
expressed GFP-tagged RhoGDI1 mutants in HeLa cells (on   
account of their high transfection efficiency) and performed   
immunoprecipitations using antibodies against GFP. The S96D 
mutation resulted in decreased association between RhoGDI 
and RhoG (Fig. 4 d). We confirmed a published report that   
the Ser
96 site does not affect Rac1 activity (Fig. S1 l; Knezevic   
et al., 2007). Thus, despite their homology, interactions of 
RhoGDI with RhoG and Rac1 are regulated differently, and   
the data are consistent with a direct effect on RhoG followed 
by an indirect effect on Rac1. Finally, we demonstrated that 
both FGF2 treatment and transfection with constitutively ac-
tive PKC result in phosphorylated Ser
96, whereas transfection 
with dominant-negative PKC diminishes this phosphorylation 
(Fig. 4 e). Collectively, these results support a model in which 
activation of PKC by S4 triggers phosphorylation of RhoGDI 
and release of RhoG, which can then be activated by GEFs that 
reside near the plasma membrane (Fig. 5).
Discussion
Rho family GTPase activation is generally a fast and transient 
event effected by local shifts in the balance between GEFs and 
GAPs. RhoGDI1 is also important in GTPase regulation. Indeed, 
knockdown of this protein results in a more than twofold in-
crease in baseline RhoG activity (Fig. 3 d). This result demon-
strates that when RhoG is not sequestered by RhoGDI1, the 
(Ota et al., 2004). Our data demonstrate that maintenance of low 
RhoG activity in the absence of FGF2 requires RhoGDI1.
We next investigated the mechanism by which RhoG   
suppression is reversed by FGF2/S4 signaling. Previous studies 
indicate that S4 oligomerization leads to the activation of   
PKC (Oh et al., 1997; Horowitz et al., 2002). To explore the 
role of this kinase in RhoG activation, we examined the effect of 
constitutively active (myristoylated) PKC on baseline RhoG 
activity. RFPECs transfected with myristoylated PKC showed 
increased RhoG activation at baseline (Fig. 4 a). Conversely,   
a dominant-negative PKC construct blocked FGF2-induced 
RhoG activation (Fig. S1 i). RhoGDI1 is among the targets of 
PKC (Price et al., 2003; Knezevic et al., 2007); therefore, 
we  hypothesized  that  PKC-dependent  phosphorylation  of 
RhoGDI1 might cause release of RhoG followed by its activa-
tion. To determine which RhoGDI1 phosphorylation site affects 
RhoG binding, RhoGDI1 constructs with mutated phosphoryla-
tion sites were screened (unpublished data). The Ser
96 residue, 
when mutated to alanine (S96A), resulted in baseline levels of 
RhoG activity that were comparable with GFP controls, whereas 
a  phosphomimetic  mutation  (S96D)  led  to  strong  activation   
of RhoG (Fig. 4 b). The S96A mutant did not suppress RhoG 
activity as efficiently as WT RhoGDI, mirroring this mutation’s 
effect on RhoA (Knezevic et al., 2007) and implying that   
alanine  substitution  at  this  site  also  moderately  weakens 
RhoGDI–RhoG binding. This result also indicates that in pre-
viously reported instances of simultaneous RhoG and RhoA   
activation (van Buul et al., 2007), the Ser
96 residue of RhoGDI1 
is a common site of regulation.
We next studied RhoGDI1 phosphorylation more directly 
with a phosphorylation site–specific antibody (validation shown 
Figure 3.  Synectin and RhoGDI1 are required 
for  RhoG  suppression  at  baseline.  (a)  WT 
murine  pulmonary  microvascular  endothelial 
cells were transfected with either GFP- or 4His-
tagged synectin 48 h before lysis and RhoG 
activity  assay.  Cells  were  serum  starved  in 
0.5% FBS/DME for 24 h before lysis. (bottom)   
Quantification from three experiments is shown. 
*,  P  =  0.052.  (b)  Mock-transfected  RFPECs   
(left  and  middle)  and  those  transfected  with 
4His-tagged synectin (right) were lysed 48 h 
after transfection. Pull-downs were performed 
using glutathione beads conjugated with GST-
RhoGDI1 (middle and right) or glutathione 
beads alone (right). (c) Lysates from WT and 
synectin knockout murine pulmonary micro-
vascular endothelial cells were normalized to 
equal protein concentrations and incubated with   
monoclonal anti-RhoGDI antibodies and pro-
tein A/G beads (+) or beads alone (). After   
washing and protein elution, the samples were 
analyzed by SDS-PAGE and probed with an 
anti-RhoG antibody. IP, immunoprecipitation.   
(d) RFPECs were transfected with a control shRNA 
sequence or shRNA specific for RhoGDI1. 24 h 
after transfection, cells were placed in 0.5% 
FBS/DME  for  an  additional  24  h,  at  which 
time they were lysed and assayed for RhoG 
activity. The quantifications show the mean of 
three experiments and reveal a more than two-
fold increase in baseline RhoG activity in cells 
treated with RhoGDI1 shRNA. * (bottom to top),   
P = 0.034 and 0.008. Error bars indicate SEM.JCB • VOLUME 186 • NUMBER 1 • 2009   80
tyrosine kinase Etk also decrease RhoGDI1–RhoA association, 
leading to RhoA activation (Kim et al., 2002; Yamashita and   
Tohyama, 2003). Although functionally opposed to synectin, ezrin 
similarly binds directly to both RhoGDI (Hirao et al., 1996) and 
syndecans (Granés et al., 2000); these observations present an-
other interesting dimension to the antagonism between ezrin and 
synectin, one that is likely to be illuminated upon discovery of 
their specific RhoGDI-binding sites.
RhoGDI1 inhibits RhoG activation by GEFs and serves as 
the physical link between S4–synectin and RhoG (Fig. 1, d and 
e; Fig. 3, b and c; and Fig. S1 b). However, conflicting studies 
describe RhoG’s ability to bind RhoGDI1 (Fauré and Dagher, 
2001; Brunet et al., 2002). In this study, the use of purified 
RhoGDI1 with a specific anti-RhoG antibody enabled us to   
definitively determine that this interaction exists (Fig. 1, d and e; 
Fig 3, b and c; and Fig. S1 b) and is functionally significant in 
RhoG activity regulation (Fig. 3 d). S4 and synectin increased 
this interaction, which may furthermore explain the failure to 
detect binding in previous studies. Although synectin was shown 
to  enhance  the  RhoGDI–GTPase  interaction  for  both  RhoG 
(Fig. 3 b) and Rac1 (Fig. S1 h), whether this effect encompasses 
additional Rho family GTPases remains to be determined.
GEF/GAP balance favors RhoG activation. We therefore sought 
to characterize the mechanism of RhoGDI-dependent GTPase 
suppression between activation cycles.
Studying the RhoGDI–RhoG interaction, we identified a 
novel multiprotein complex of S4–synectin–RhoGDI1 as the 
central regulatory component of RhoG activity. The contribu-
tions of each protein were then characterized beginning with 
S4. A single amino acid deletion in the PDZ-binding domain 
of S4 diminished the efficiency of ternary complex formation 
(Fig. 2 c). This finding explains previous results that a mutated 
PDZ-binding domain results in elevated Rac1 levels (Tkachenko 
et al., 2006) and demonstrates the importance of S4 in stabiliz-
ing the complex.
Synectin was also found to be an indispensable component 
of the ternary RhoG regulation complex. Our data are the first to 
describe a protein that enhances the affinity of RhoGDI1 for a 
GTPase (Fig. 3, a–c), although studies have characterized pro-
teins that perform the opposite role: the ezrin–radixin–moesin 
(ERM)-CD44 system, involved in actin reorganization, is a di-
rect binding partner of RhoGDI that decreases the affinity of the 
GDI for Rho GTPases (Hirao et al., 1996; Takahashi et al., 1997). 
Furthermore, the neurotrophin receptor p75
NTR and nonreceptor 
Figure 4.  PKC phosphorylation of RhoGDI1 at Ser
96 in-
duces RhoG activation. (a) RFPECs were transduced with GFP 
or GFP-myristoylated PKC adenoviral constructs for 48 h   
before RhoG activity assay. The cells were serum starved in 
0.5% FBS/DME 24 h after transfection, at which time lysates   
were collected. (bottom) Quantification for three experi-
ments is shown. *, P = 0.048 (two-sample equal variance t test).   
(b) RFPECs were transfected with the indicated constructs for 
24 h and serum starved in 0.5% FBS/DME for an additional 
24 h before RhoG activity assay. Expression of phospho-
mimetic RhoGDI1 (S96D) led to RhoG activation. Quantifica-
tion represents the mean of three experiments. *, P = 0.038. 
(c) RFPECs with stable expression of the S4-FcR chimera were 
used to cluster the transmembrane and cytosolic domains of 
S4. These cells were treated with 2 µg/ml nonimmune human 
IgG and washed twice with PBS. Clustering was initiated 
with anti–human IgG F(ab)2 fragments at 3 µg/ml for the   
indicated times. Cells were lysed and analyzed by immuno-
blotting. A rabbit polyclonal antibody specific for the phos-
phorylation of Ser
96 was used for the top panel. (d) HeLa cells 
overexpressing the indicated GFP-tagged RhoGDI1 mutants 
were lysed 72 h after transfection and subjected to immuno-
precipitation  (IP)  with  anti-GFP  antibodies  conjugated  to 
protein A/G beads. The immunoblot was probed for RhoG. 
RhoGDI1 (S96D) leads to decreased RhoG–RhoGDI1 inter-
action. (e) RFPECs were transfected with the indicated con-
structs and serum starved. FGF2 treatment was performed 
for 1 min. Lysates were subsequently analyzed by Western 
blotting using anti–phospho-RhoGDI (Ser
96) antibodies. Both 
FGF2  and  (myristoylated)  constitutively  active  (CA)  PKC 
resulted in RhoGDI1 phosphorylation Ser
96, whereas kinase-
dead (KD) PKC resulted in a lower baseline level of RhoGDI 
phosphorylation at this residue. Error bars represent SEM.81 SYNDECAN 4 REGULATES RhoG ACTIVITY • Elfenbein et al.
revealed a mechanism to explain these earlier reports that the S4 
PDZ-binding domain is crucial for GTPase regulation: the PDZ-
binding domain mediates the S4–synectin interaction and en-
hances the latter’s affinity for RhoGDI1 (Fig. 2 c). Additionally, 
our observations substantiate the involvement of PKC by show-
ing that this kinase phosphorylates RhoGDI1, releasing RhoG to 
activate Rac1 (Fig. 4).
More importantly, we found that the S4–synectin–RhoGDI1 
complex mediates the baseline suppression of RhoG. How such 
GTPases are constitutively maintained in their inactive states has 
been poorly understood, and our data reveal the mechanism by 
which S4 and synectin are required for this process. Disrupting 
any part of the S4–synectin–RhoGDI1 complex (by gene silencing 
or mutagenesis) creates a persistently dysregulated state of active 
RhoG by decreasing its binding to RhoGDI1 (Fig. 2 a; and Fig. 3, 
a and d). Although this invariably leads to a high baseline level of 
RhoG and Rac1 activity, FGF2 stimulation is still able to further 
activate these GTPases in cells lacking S4 or synectin (Chittenden 
et al., 2006). This result implies that the S4–synectin–RhoGDI1 
complex mediates the sequestration and release of inactive RhoG 
but is dispensable for actual activation event, which is presumably 
catalyzed by a yet undetermined GEF. In the case of FGF2 signal-
ing, it is likely that activation of this GEF proceeds downstream of 
FGF tyrosine kinase receptor (FGFR1–4) signaling.
In animal models, genetic deletions of S4, synectin, or 
RhoGDI1 result in pronounced vascular phenotypes (both de-
velopmental and homeostatic) that include arterial branching 
defects, endotoxic shock susceptibility, elevated blood pres-
sure, and enhanced pulmonary vessel permeability (Ishiguro   
et al., 2001; Chittenden et al., 2006; Gorovoy et al., 2007; 
Partovian et al., 2008). Neural crest formation in Xenopus 
laevis and zebrafish are also dependent on S4/Rac1 signaling 
(Matthews et al., 2008), and other neural implications of S4–
synectin–RhoGDI1 disruption are likely to parallel those dis-
covered in the vascular system.
Given the breadth of molecular and physiological influ-
ence exerted by the S4–synectin–RhoGDI1 complex, we believe 
Published studies involving RhoGDI2 (Ly-GDI or GDI-
D4) have shown the ability of this GDI to affect the activity 
states and localization of Rho GTPases (Ota et al., 2004), and 
we  investigated  whether  RhoGDI1  likewise  determines  the   
localization and activity of RhoG. Our finding that the Ser
96 
site is phosphorylated to release RhoG from RhoGDI is sup-
ported by related published findings. First, RhoGDI1 is phos-
phorylated by p21-activated kinase on two sites, causing Rac1 
activation (DerMardirossian et al., 2004). RhoGDI1 Ser
96 also 
becomes phosphorylated by PKC and is involved in RhoA 
activation (Knezevic et al., 2007). Given that RhoA and RhoG 
are often activated simultaneously (van Buul et al., 2007), it 
is likely that Ser
96 phosphorylation determines the activity of 
both GTPases similarly.
Finally, our confirmation of the observation that Ser
96 phos-
phorylation does not affect Rac1 activity (Knezevic et al., 2007) 
indicates an important point of departure between RhoG and 
Rac1; these two proteins have high sequence homology, are part 
of the same signaling pathway, are activated with similar kinetics, 
and both bind to RhoGDI1. However, we demonstrate that activa-
tion via Ser
96 phosphorylation affects only RhoG. Although criti-
cal in FGF2 signaling, RhoG is not common to all signaling 
cascades that converge upon Rac1. For example, syndecans and 
integrins contribute synergistically but distinctly to GTPase   
activation (Bass et al., 2007), and integrin-mediated Rac1 activa-
tion does not require RhoG (Meller et al., 2008). In the case of 
FGF2 stimulation, the finding that A37 RhoG blocks Rac1 activa-
tion (Fig. 1 c) strongly suggests ELMO1–Dock180 involvement 
(Katoh and Negishi, 2003), although other parallel RhoG-
  dependent modes of Rac1 activation could also contribute.
Previous studies indicated that S4 orchestrates the polar-
ization of active Rac1 in the presence of chemotactic signals 
such as FGF2 and that S4 induces Rac-dependent cell migration 
in a manner that requires both its PDZ-binding domain and 
PKC (Tkachenko et al., 2006; Bass et al., 2007). This study 
unifies these observations with the discovery of the S4–synec-
tin–RhoGDI1 protein complex. Examining this ternary complex 
Figure 5.   RhoG activation is regulated by a 
S4–synectin–RhoGDI1 complex. RhoG activity 
is suppressed at baseline by a complex con-
sisting of S4, synectin, and RhoGDI1. Within 
this complex, S4 enhances synectin–RhoGDI1 
binding, and synectin increases the affinity of 
RhoGDI1  for  RhoG.  Upon  FGF2  stimulation 
and subsequent S4 oligomerization, PKC be-
comes activated, which phosphorylates RhoGDI 
at  its  Ser
96  residue.  This  induces  the  disso-
ciation  of  RhoG  from  RhoGDI1,  after  which 
RhoG becomes activated. Active RhoG asso-
ciates with ELMO1 and Dock180 to form a 
functional GEF complex, which is required for 
Rac1 activation in this pathway.JCB • VOLUME 186 • NUMBER 1 • 2009   82
Upon stimulation for the indicated times, the cells were lysed on ice with 
M-PER (Thermo Fisher Scientific) supplemented with Complete Protease In-
hibitor Cocktail (Roche). GST-ELMO1–conjugated beads were incubated 
with cell lysates at 4°C for 30 min before being washed four times and 
boiled in SDS-PAGE sample buffer (Thermo Fisher Scientific). Eluted pro-
teins were subjected to immunoblot analysis and probed with either anti-
RhoG or anti-Rac1 antibodies. The RhoG pull-down assay was validated 
using  constitutively  active  (V12)  RhoG  and  effector  nonbinding  (A37) 
RhoG as controls.
Immunoprecipitations, GST-tagged protein pull-downs, and Western blots
Cells were lysed using either M-PER or RIPA buffers (Thermo Fisher Scien-
tific) containing Complete Mini Protease Inhibitor Cocktail (Roche) for 
immunoprecipitations, pull-downs, and Western blots. For immunoprecipi-
tations, protein A/G sepharose beads (GE Healthcare) were conjugated with 
the corresponding antibodies and incubated with cell lysates overnight at 4°C. 
They were washed six times with lysis buffer, immersed in sample buffer 
(Thermo Fisher Scientific), boiled for 5 min, and analyzed by SDS-PAGE. 
GST-tagged RhoGDI pull-downs were performed similarly with glutathione 
agarose beads (Thermo Fisher Scientific) used instead of sepharose and 
purified GST-RhoGDI1 (Cytoskeleton, Inc.) used as bait. Biotinylated S4 tail 
pull-downs were performed using streptavidin-conjugated beads (Thermo 
Fisher Scientific). 10% polyacrylamide gels (Bio-Rad Laboratories) were 
used for all Western blots.
Microscopy
Live cell imaging of FRET probes was performed by excitation of CFP and 
measurement of both CFP and YFP emission in cells transfected with the in-
dicated probes (Aoki et al., 2005). These experiments were performed   
using an environment-controlled (set to 37°C) widefield microscope (IX-81; 
Olympus) using an oil immersion 60× NA 1.4 objective (Olympus). Meta-
Morph software was used for acquisition. The filters used for the dual-
emission imaging were obtained from Omega Optical: an excitation filter 
(XF1071), a dichroic mirror (XF2034), and two emission filters (XF3075 
for CFP and XF3079 for FRET). The imaging medium was phenol red–free 
DME/F12 (1:1 ratio) supplemented with 1% BSA and covered by mineral 
oil (Sigma-Aldrich) to prevent evaporation. The camera used for these ex-
periments was a CoolSNAP HQ model (Roper Scientific). Cell migration 
was performed by introducing scratch wounds to confluent monolayers of 
RFPECs and measuring migration after 24 h using a 10× NA 0.3 objec-
tive (Olympus).
Fixed  sections  were  prepared  by  transfer  of  cells  growing  on   
fibronectin-coated glass-bottom dishes to ice, washing once with ice-cold 
PBS, and fixation with 4% paraformaldehyde/PBS at room temperature for 
10 min. Samples were washed three times with PBS and incubated with 
0.1% Triton X-700 for 10 min for permeabilization where indicated. They 
were blocked with 1% BSA/PBS for 30 min at room temperature before 
antibody incubation. Confocal imaging of fixed cells was performed at 
room temperature with PBS as imaging medium using an FV1000 system 
(Olympus) equipped with an oil immersion 60× NA 1.35 objective (Olym-
pus) with FluoView software (Olympus) for acquisition. All figures were as-
sembled using Photoshop and Illustrator software (Adobe).
Quantitative analyses
Cellular distributions of GFP-RhoG were quantified by creating 20 line 
scans of equal length (five cells with four line scans per condition) with their 
midpoints at the cell membrane. The intensity at each pixel was measured 
using ImageJ software (National Institutes of Health) and was averaged 
among corresponding pixels in all line scans of each condition. Each inten-
sity reading was normalized to the highest observed intensity across all 
conditions. Western blots were scanned using either the G:Box (Syngene) 
or the Odyssey (LI-COR Biosciences) and quantified using GelEval software 
(FrogDance). FRET ratio analyses were performed using MetaMorph soft-
ware. Cell migration was quantified using ImageJ software.
Online supplemental material
Fig. S1 shows Rac1 activation upon FGF2 treatment, RhoG knockdown 
and basal Rac1 activity, RhoGDI1 expression and the cellular distribution 
of RhoG, RhoG antibody validation for immunofluorescence applications, 
RhoG activity at baseline in synectin knockout endothelial cells, the effect 
of synectin overexpression on Rac1 binding to RhoGDI1, dominant-negative 
PKC and FGF2-induced RhoG activation, the phospho-RhoGDI1 (Ser
96) 
antibody specificity in Western blot analyses, and phosphomimetic and 
nonphosphorylatable mutations of RhoGDI1 (Ser
96) and baseline Rac1 ac-
tivity. Online supplemental material is available at http://www.jcb.org/ 
cgi/content/full/jcb.200810179/DC1.
it represents a significant mechanism of GTPase regulation. Our 
data identify novel functions of both S4 and synectin in GTPase 
signaling, characterize the pathway of S4-mediated Rac1 acti-
vation during endothelial migration, and address the longstand-
ing question of how Rho GTPases are maintained in a minimally 
activated state before growth factor stimulation.
Materials and methods
Cell culture, transfection, and transduction
RFPECs and HeLa cells were cultured in DME (Cambrex) containing 10% 
FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin (Mediatech). RFPECs 
with stable expression of the S4-FcR and S4-FcR (PDZ) chimeras (Tkachenko 
and Simons, 2002) were used for S4 clustering experiments. The S4-FcR 
(PDZ) mutant includes a single amino acid truncation at the cytoplasmic 
terminus (Horowitz et al., 2002). Primary pulmonary murine endothelial cells 
from WT and S4 knockout mice were isolated by harvesting murine lungs 
and subjecting them to fine mincing and digestion in 25 ml collagenase 
0.2% (wt/vol) at 37°C for 45 min. The crude cell preparation was pelleted 
and resuspended in Dulbecco’s PBS. The cell suspension was incubated with 
PECAM-1–coated beads (IgG Dynal beads; Invitrogen) at room temperature 
for 10 min with end over end rotation. Using a magnetic separator, the 
bead-bound cells were recovered, washed with DME containing 20% FBS, 
suspended in 12 ml complete culture medium (DME containing 20% fetal 
calf serum supplemented with 100 ug/ml heparin, 100 ug/ml endothelial 
cell growth factor growth supplement [Biomedical Technologies], and non-
essential amino acids, sodium pyruvate, L-glutamine, and antibiotics at stan-
dard concentrations), and plated in fibronectin-coated 75-cm
2 tissue culture 
flasks. Transfection of RFPECs was performed using Fugene6 (Roche) or 
Amaxa (Amaxa, Inc.), and transfection of HeLa cells was performed using 
293Fectin (Invitrogen) according to the manufacturer’s protocols. Adenoviral 
transduction was performed using 100 MOI.
cDNA constructs
GFP- and myc-tagged RhoG and GST-ELMO1 constructs were provided by 
H. Katoh and M. Negishi (Kyoto University, Kyoto, Japan). The S4-FcR chi-
mera was previously generated (Tkachenko et al., 2006). Synectin constructs 
were provided by A. Horowitz (Dartmouth Medical School, Hanover, NH). 
The RhoG shRNA construct targets nucleotides 348–367 (5-CGTCTTCGT-
CATCTGTTTC-3). GFP-tagged RhoGDI1 constructs were provided by   
D.  Mehta (University of Illinois, Chicago, IL). Myc-tagged RhoGDI1, the 
Vav2 expression construct, and Raichu-Rac1 FRET probes were validated 
previously (Aoki et al., 2005; Moissoglu et al., 2006; Tkachenko et al., 
2006). The adenoviral dominant-negative PKC construct was cloned with a 
PKC epitope tag (Horowitz et al., 1999).
Antibodies and reagents
Rabbit  polyclonal  antisynectin  antibodies  and  mouse  monoclonal  anti-
RhoG  antibodies  were  generated  previously  (Chittenden  et  al.,  2006; 
Meller et al., 2008). Phospho-specific RhoGDI1 Ser
96 antibodies were gen-
erated by and in consultation with 21st Century Biochemicals, Inc. to the 
following  sequence,  which  is  conserved  in  mouse,  rat,  and  human: 
LDLTGDLE[pS]FKKQSFV. Mouse monoclonal anti-GFP antibodies and rab-
bit polyclonal anti-RhoGDI1 antibodies were purchased from Santa Cruz 
Biotechnology, Inc. Mouse monoclonal anti– actin antibodies were ob-
tained from BD. Mouse monoclonal anti-RhoG antibodies and GST-tagged 
RhoGDI1 were purchased from Cytoskeleton, Inc. Biotinylated S4 tail pep-
tide (biotin-MKKKDEGSYDLGKKPIYKKAPTNEFYA) corresponding to the 
C-terminal protein sequence was synthesized by Syngene and verified by 
mass spectrometry. Nonimmune human IgG and anti–human F(ab)2 frag-
ments were purchased from Jackson ImmunoResearch Laboratories. FGF2 
was obtained from Novartis.
Rac1 and RhoG activity assays
ELISA-based Rac1 activity quantification was performed using the G-LISA 
kit (Cytoskeleton, Inc.) according the manufacturer’s protocol. RhoG pull-
down assays were performed by first purifying GST-ELMO1 and conjugat-
ing  it  to  agarose  beads  using  a  GST  Purification  kit  (Thermo  Fisher 
Scientific). Rac1 pull-down assays were performed using p21-activated 
kinase–conjugated agarose beads (Cytoskeleton, Inc.). With the exception 
of these baits, both Rac1 and RhoG pull-downs were performed identically 
as follows: cells were serum starved in 0.5% FBS/DME for 24 h before assay. 83 SYNDECAN 4 REGULATES RhoG ACTIVITY • Elfenbein et al.
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